The Central Government amended the Drugs Rules, 1945, establishing centralized licensing for stem cell therapies, gene therapies, and xenografts under the CLAA framework. This reform ensures uniform oversight, promotes clinical safety, and targets unproven, exploitative medical practices across India.
Click to View MoreA Phase I trial reported in The Lancet shows in-utero stem cell therapy for myelomeningocele is safe and feasible. Placenta-derived mesenchymal stem cells applied during fetal surgery improved healing. For India, with high birth-defect incidence, it may reduce lifelong burdens and support early detection goals of RBSK.
Click to View More
© 2026 iasgyan. All right reserved
